so if by "placebo" group they mean the ones who didn't receive Ty during the study, then during the "3 months after discontinuation of therapy" the non-placebo group progressed at a faster rate (to catch up) than the placebo group? so, to me that is a "bounce-back", limited, but still.A phase II study failed to demonstrate a difference between natalizumab treatment groups and the placebo group with regard to gadolinium enhancing lesions on MRI 3 months after discontinuation of therapy.
The blood brain barrier and neurons
- CureOrBust
- Family Elder
- Posts: 3374
- Joined: Wed Jul 27, 2005 2:00 pm
- Location: Sydney, Australia
Thanks dignan, still one thing I am not certain I understand about this study, is that in my mind, I would expect that Ty would cause a lowering of lesions while you are on it (compared to those on placebo). If NO "bounce back" effect was noticed, then you would expect that at the end of 3 months off the therapy, you would expect the ones who never took Ty, would be worse off than those who did take it during the trial; ie they started the 3 months from a point of more lesions.
- CureOrBust
- Family Elder
- Posts: 3374
- Joined: Wed Jul 27, 2005 2:00 pm
- Location: Sydney, Australia
- CureOrBust
- Family Elder
- Posts: 3374
- Joined: Wed Jul 27, 2005 2:00 pm
- Location: Sydney, Australia